gastric cancer

Showing 10 posts of 10 posts found.

FDA approves Merck’s Keytruda for gastric cancer treatment

November 17, 2023
Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda

Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …

Merck’s Keytruda approved by EC for gastric cancer

August 30, 2023
Research and Development EC, Merck, Oncology, gastric cancer, keytruda

Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …


Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans

December 11, 2017
Research and Development, Sales and Marketing Cancer, Eli Lilly, cyramza, gastric cancer, pharma

Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …

Merck researcher

Merck/Pfizer Alliance to collaborate on late-stage cancer trials

December 10, 2015
Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …

erbitux image

Erbitux fails in gastric cancer trial

July 6, 2012
Research and Development, Sales and Marketing Erbitux, Merck Serono, Roche, failure, gastric cancer

Merck’s Erbitux has failed to increase survival in patients with gastric cancer, representing a blow to the firm’s ambition to …

NICE recommends Herceptin for gastric cancer, blocks high dose Glivec

November 24, 2010
Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer

NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …

Herceptin packs

NICE set to block Herceptin for gastric cancer

July 6, 2010
Sales and Marketing Herceptin, NICE, Roche, gastric cancer

NICE’s preliminary draft guidance has not approved Roche’s Herceptin for gastric cancer as it failed to show how far the …

Avastin fails in phase III study

February 24, 2010
Research and Development Roche, avastin, gastric cancer, stomach cancer

Roche’s Avastin does not help patients with a severe form of stomach cancer to live longer, according to the results …

Roche expands Herceptin franchise

February 8, 2010
Sales and Marketing Herceptin, Roche, gastric cancer, stomach cancer

Roche’s blockbuster breast cancer treatment Herceptin has been launched in the UK as a treatment for stomach cancer. It is …

Latest content